SUPRIYA vs TORNTPHARM: Stock Comparison
TORRENT PHARMACEUTICALS L is the larger company by market capitalisation. SUPRIYA LIFESCIENCE shows a lower P/E, faster revenue growth and lower leverage, while TORRENT PHARMACEUTICALS L shows a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SUPRIYA leads 9; TORNTPHARM leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SUPRIYA | TORNTPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | SUPRIYA | TORNTPHARM |
|---|---|---|
| Live Price | ₹862.15 | ₹4,635.8 |
| Day Change | -0.82% | 1.22% |
| Volume | 37,845 | 94,679 |
| 52-Week High | ₹1,085 | ₹5,250 |
| 52-Week Low | ₹545.5 | ₹3,532.6 |
| Distance from 52W High | -20.54% | -11.7% |
Valuation
| Metric | SUPRIYA | TORNTPHARM |
|---|---|---|
| Market Cap | ₹6,950 Cr | ₹1.76 L Cr |
| P/E Ratio | 35.11x | 74.8x |
| P/B Ratio | 5.82x | 8.41x |
| EPS | ₹2.99 | ₹14.04 |
| Book Value | ₹148.82 | ₹462.32 |
| Dividend Yield | 0.12% | 0.83% |
Growth
| Metric | SUPRIYA | TORNTPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 50.2% | 41.8% |
| EPS Growth (TTM YoY) | 46.7% | -21.7% |
| Qtr Sales Growth | 0% | 1.18% |
| Qtr Profit Growth | 0% | -5.65% |
Profitability & Leverage
| Metric | SUPRIYA | TORNTPHARM |
|---|---|---|
| ROE | 17.46% | 25.93% |
| ROCE | 19.21% | 10.87% |
| Net Margin | 25.26% | 15.73% |
| Operating Margin | 33.42% | 30.23% |
| Debt to Equity | 0x | 1.68x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | SUPRIYA | TORNTPHARM |
|---|---|---|
| Promoter Holding | 68.3% | 60.78% |
| FII Holding | 6.44%▲ 0.25 pp | 17.22%▼ 0.75 pp |
| DII Holding | 5.47%▲ 0.17 pp | 13.46%▲ 0.59 pp |
| Public Holding | 19.79%▼ 0.42 pp | 8.54%▲ 0.16 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUPRIYA LIFESCIENCE and TORRENT PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.